|Page (1) of 1 - 02/27/17||email article||print page|
(February 27, 2017)
EDEN PRAIRIE, Minn., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (NASDAQ:SSH) announced today that the company will partner with the American Association of Heart Failure Nurses (AAHFN) at the Advanced Heart Failure Symposium in Tampa, FL on March 3-4, 2017 at the Center for Advanced Medical Learning and Stimulation (CAMLS). The two-day symposium will provide an in-depth perspective on the treatment of patients with advanced heart failure.
“Since acquiring the Aquadex business, we have received a great deal of interest in expanding the use of Aquapheresis and we are committed to supporting our patients and clinical partners with information on best practices from experts in the field” said John Erb, Chairman and CEO of Sunshine Heart. “We are excited about the expanded use of this valuable therapy to aid hospitals in reducing frequency of hospitalization and length of stay.”
Sunshine Heart will be sponsoring a lunch practicum delivered by Cindy Bither, Nurse Practitioner at Washington MedStar Hospital and current President of AAHFN. The presentation will foster discussion on the role of ultrafiltration to manage fluid overload in heart failure and focus on disseminating best practices from expert users of Aquapheresis therapy. The AAHFN and Sunshine Heart share a passion for providing education to Nurses and Nurse Practitioners who manage advanced heart failure across practice settings. This forum provides an outstanding opportunity to continue this service of education.
“We are discussing Aquapheresis in the Advanced Heart Failure program because there is a group of HF patients that are diuretic resistant and need relief of symptoms,” said Cindy Blither. “Patient outcomes are dependent on appropriate therapy plans and the skill of the nurse who is carrying out that plan.”
About Sunshine Heart®
Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company focused on commercializing the Aquadex FlexFlow® System. The Company's commercial product, the Aquadex system, is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. Our objective is to improve the quality of life for heart failure patients and slow the disease progression. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.
Certain statements in this release are forward-looking statements that are based on management’s beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation, clinical and pre-clinical study designs and activities, expected timing for initiation, enrollment and completion of clinical trials, research and development activities, ultimate clinical outcomes and benefits of our products to patients, design and development of future studies, site activations,  patient enrollment in studies, timing of regulatory filings and approvals, regulatory acceptance of our filings, our expectations with respect to product development and commercialization efforts, market and physician acceptance of our products, intellectual property protection, and potentially competitive product offerings. The risk factors described in our filings with the SEC could cause actual events to adversely differ from the expectations indicated in these forward-looking statements. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sunshine Heart does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Sunshine Heart may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including without limitation, the possibility that regulatory authorities do not accept our application or approve the marketing of our therapy, the possibility we may be unable to raise the funds necessary for the development and commercialization of our therapy and other risks and uncertainties described in our filings with the SEC. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: For further information, please contact: Claudia Napal Drayton Chief Financial Officer Sunshine Heart, Inc. T: +1-952-345-4205 Investor RelationsSunshine Heart [email protected]
Related Sites: HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter